Regeneron Pharmaceuticals, Inc. targets double-digit 2026 growth via Dupixent expansion and fewer Eylea headwinds. Check out ...
Investor's Business Daily on MSN
Regeneron falls, but hints that it could be ready to flex its dealmaking muscles
Regeneron stock fell Friday, but an analyst suggested the company could seek deals following a solid fourth-quarter report.
If you are wondering whether Regeneron Pharmaceuticals is attractively priced right now, it helps to separate the headlines ...
Jan 30 (Reuters) - U.S. drugmaker Regeneron Pharmaceuticals beat analysts' estimate for fourth-quarter profit on Friday, ...
Biotech company Regeneron (NASDAQ:REGN) will be reporting earnings this Friday before market open. Here’s what investors ...
By Gnaneshwar Rajan and Sriparna Roy Jan 30 (Reuters) - Regeneron Pharmaceuticals' executives voiced confidence in its ...
Regeneron beat Q4 earnings and sales estimates as Dupixent gains offset weaker Eylea sales. The drugmaker also outlined 2026 ...
Regeneron Pharmaceuticals has recently drawn renewed attention as investment funds, Wall Street analysts, and industry ...
Earlier this month at the J.P. Morgan Healthcare Conference, Regeneron got its Eylea sales news out of the way. | For the ...
The Regeneron Science Talent Search 2026 finalists represent 35 schools across 15 states. They are competing for more than $1.8 million, with a top prize of $250,000 to further their scientific ...
Regeneron (REGN) stock in focus as the company posts Q4 2025 beat as its revenue tied to Sanofi (SNY) partnership offsets headwinds to Eylea franchise. Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results